niacinamide has been researched along with Adjuvant Arthritis in 8 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here we investigated the effect of nicaraven (2(R,S)-1,2-bis(nicotinamido)propane), a known hydroxyl radical scavenger compound and neuroprotective agent, on several NO- and peroxynitrite related pathways in vitro, and in shock and inflammation in vivo." | 7.70 | Effects of nicaraven on nitric oxide-related pathways and in shock and inflammation. ( Hake, P; Salzman, AL; Scott, GS; Szabo, C; Zingarelli, B, 2000) |
| " Here we investigated the effect of nicaraven (2(R,S)-1,2-bis(nicotinamido)propane), a known hydroxyl radical scavenger compound and neuroprotective agent, on several NO- and peroxynitrite related pathways in vitro, and in shock and inflammation in vivo." | 3.70 | Effects of nicaraven on nitric oxide-related pathways and in shock and inflammation. ( Hake, P; Salzman, AL; Scott, GS; Szabo, C; Zingarelli, B, 2000) |
| " Furthermore, peficitinib dose-dependently suppressed bone destruction and paw swelling in an adjuvant-induced arthritis model in rats via prophylactic or therapeutic oral dosing regimens." | 1.46 | A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model. ( Chida, N; Higashi, Y; Inami, M; Inoue, T; Ito, M; Kuno, M; Morita, Y; Nakamura, K; Okuma, K; Shirakami, S; Yamagami, K; Yamazaki, S, 2017) |
| "Oral administration of ML120B inhibited paw swelling in a dose-dependent manner (median effective dosage 12 mg/kg twice daily) and offered significant protection against arthritis-induced weight loss as well as cartilage and bone erosion." | 1.33 | IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis. ( Anderson, K; Chandra, S; DuPont, M; Gangurde, P; Harriman, G; Hepperle, M; Jaffee, B; Kujawa, J; Lane, J; Morgan, J; Ocain, T; Savinainen, A; Schopf, L; Siebert, E; Silva, M; Wen, D; Xu, Y, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ishikawa, G | 1 |
| Kwon, C | 1 |
| Fujii, Y | 1 |
| Ji, G | 1 |
| Neugebauer, V | 1 |
| Ito, M | 1 |
| Yamazaki, S | 1 |
| Yamagami, K | 1 |
| Kuno, M | 1 |
| Morita, Y | 1 |
| Okuma, K | 1 |
| Nakamura, K | 1 |
| Chida, N | 1 |
| Inami, M | 1 |
| Inoue, T | 1 |
| Shirakami, S | 1 |
| Higashi, Y | 1 |
| Schopf, L | 2 |
| Savinainen, A | 1 |
| Anderson, K | 1 |
| Kujawa, J | 1 |
| DuPont, M | 1 |
| Silva, M | 1 |
| Siebert, E | 1 |
| Chandra, S | 1 |
| Morgan, J | 1 |
| Gangurde, P | 1 |
| Wen, D | 1 |
| Lane, J | 1 |
| Xu, Y | 2 |
| Hepperle, M | 2 |
| Harriman, G | 2 |
| Ocain, T | 2 |
| Jaffee, B | 2 |
| Izmailova, ES | 1 |
| Paz, N | 1 |
| Alencar, H | 1 |
| Chun, M | 1 |
| Lane, JH | 1 |
| Weissleder, R | 1 |
| Mahmood, U | 1 |
| Healy, AM | 1 |
| Kalia, R | 1 |
| Rao, CM | 1 |
| Kutty, NG | 1 |
| Kröger, H | 1 |
| Dietrich, A | 1 |
| Grätz, R | 1 |
| Klewer, M | 1 |
| Wohlert, H | 1 |
| Ehrlich, W | 1 |
| Zingarelli, B | 1 |
| Scott, GS | 1 |
| Hake, P | 1 |
| Salzman, AL | 1 |
| Szabo, C | 1 |
8 other studies available for niacinamide and Adjuvant Arthritis
| Article | Year |
|---|---|
Comparison of the effects of peficitinib and tofacitinib in the adjuvant-induced arthritis rat model.
Topics: Animals; Arthritis, Experimental; Janus Kinase Inhibitors; Niacinamide; Rats; Vascular Endothelial G | 2023 |
CB1 augments mGluR5 function in medial prefrontal cortical neurons to inhibit amygdala hyperactivity in an arthritis pain model.
Topics: Amygdala; Animals; Arachidonic Acids; Arthritis, Experimental; Cannabinoid Receptor Agonists; Evoked | 2014 |
A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model.
Topics: Adamantane; Adjuvants, Immunologic; Administration, Oral; Animals; Arthritis, Experimental; Cell Pro | 2017 |
IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Bone and Bones; Carbolines; Cartilage; Dise | 2006 |
Use of molecular imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis.
Topics: Administration, Oral; Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; | 2007 |
Synthesis and evaluation of the antiinflammatory activity of N-[2-(3,5-di-tert-butyl-4-hydroxyphenyl)-4-oxo-thiazolidin-3-yl]-nicotinamide.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Arthritis, Exp | 2007 |
The influence of antagonists of poly(ADP-ribose)polymerase on the activity of antirheumatic drugs on the development of adjuvant arthritis in rats and on the induction of tyrosine aminotransferase in the liver of rats.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Benzamides; Caffeine; Enzyme Induction; Enzy | 1996 |
Effects of nicaraven on nitric oxide-related pathways and in shock and inflammation.
Topics: Animals; Antioxidants; Arthritis, Experimental; Carrageenan; Dose-Response Relationship, Drug; Edema | 2000 |